February 7, 2014
Difficulties With Monitoring
Meanwhile, liver monitoring and HCV disease staging have typically meant conducting a biopsy -- which, though it can be helpful for diagnosis of other forms of liver disease, can inform the need for HCC screening and can effectively predict end-stage liver disease development, is also expensive, invasive and quite painful. "We don't find a lot of patients particularly eager to undergo that."
The validity of a biopsy can also sometimes be a matter of debate, due to the risk that the liver sample taken may -- depending on the cross section of the organ obtained -- misrepresent the total amount of fibrosis. Due to the discomfort involved in the procedure, repeated testing is often less than ideal for many patients.
Meanwhile, other typical forms of non-invasive tests have limited value when it comes to determining HCV disease stage, Cox said. Measuring HCV RNA levels can have important prognostic value; determining HCV genotype is key to informing the type and duration of therapy to use; and CT scans or MRIs can spot evidence of cirrhosis. But none of these methods are effective at staging a patient's disease, Cox said, which has historically been critical for gauging whether treatment should be initiated.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|An Airplane, a Missile, and an Unfathomable Moment in the War Against HIV|
|No Longer Cured: HIV Relapse in "Mississippi Child" Raises New Questions|
|I'm an HIV Physician. And I'm Starting PrEP. A Blog Entry by Howard Grossman, M.D.|
|Coverage of AIDS 2014: The 20th International AIDS Conference|
|AIDS 2014 to Focus on Scaling Up What Works|
|Amidst Sadness, AIDS 2014 to Proceed as Global HIV Community Mourns Lost Leaders|